Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  HALO, CLDA,ZIOP

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

HALO, CLDA,ZIOP

38 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  1. [verwijderd] 15 februari 2011 10:44
    HALO, CLDA,ZIOP
    En de connectie met:
    Randal J. Kirk

    en.wikipedia.org/wiki/Randal_J._Kirk

    Boardmember:

    Clinical Data, Inc. (2004)
    Halozyme Therapeutics, Inc., a biopharmaceutical company (2007)
    Intrexon Corporation (2008)
    Board of Visitors of Radford University (2003), Rector of the Board (2006)
    Radford University Foundation, Inc. (1998)
    Virginia Advisory Council on Revenue Estimates (2006)
    Virginia University Research Partnership (2007)
    Scios Inc. (past)

    In February 2007 he sold New River Pharmaceutical to Shire plc

    Holdings:

    biz.yahoo.com/t/74/657.html

    News:

    blogs.forbes.com/robertlangreth/2011/...

    www.dailyfinance.com/story/stock-pick...

    www.halozyme.com
    www.CLDA.com
    www.ziopharm.com

    DYODD

    Dirk
  5. [verwijderd] 15 februari 2011 19:49
    US HOT STOCKS: Nasdaq,

    Clinical Data Inc. (CLDA, $32.41, +$2.89, +9.79%) shares rose after the company withdrew from an investor conference this morning. Wedbush said the move suggests that "acquisition activity" is heating up and boosts its price target to $42 from $28. The firm notes that management has previously said it was open to a change in control after last month's FDA approval of Viibryd to treat major depressive disorder. Clinical Data officials declined to comment.

    custom.marketwatch.com/custom/tdameri...

    :->#)

    Dirk
  8. [verwijderd] 16 februari 2011 12:05
    Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)

    Last update: 2/16/2011 1:00:00 AM-

    Subcutaneous MabThera formulated with Halozyme's recombinant human enzyme - - Halozyme to receive milestone payment of $5 million

    - SAN DIEGO, Feb. 16, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. (HALO) and Roche (six:RO)(six:ROG)(otcqx:RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze((TM) technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin(R) SC (trastuzumab), to enter a Phase 3 registration study as part of the Halozyme-Roche collaboration. Initiation of the clinical trial has triggered a milestone payment of $5 million to Halozyme. MabThera is approved to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) using different induction and maintenance treatments that are currently given intravenously (IV).

    "The start of this Phase 3 subcutaneous MabThera trial in patients with follicular NHL signifies another major achievement for the Halozyme-Roche partnership, and represents the second Roche target to begin a pivotal trial. I congratulate the team on this important accomplishment," said Gregory Frost, Ph.D., Halozyme's president and CEO. "MabThera is the standard of care for several serious forms of blood cancer and we expect this subcutaneous alternative could provide a compelling administration option."

    This innovative technology may allow patients with NHL to receive MabThera in less than 10 minutes via a simple SC injection at their physician's office. Administration of SC MabThera means that patients with NHL undergoing induction therapy or completing two years of maintenance treatment with MabThera would have the greater convenience of being able to receive a much shorter drug administration, a compelling and welcome benefit.

    Offering SC MabThera treatment outside of the IV infusion center or hospital setting could also reduce costs and potentially help to maximize the efficient use of hospital resources. Additional information about this Phase 3 SC MabThera clinical trial can be found at clinicaltrials.gov and roche-trials.com.

    Halozyme-Roche Collaboration In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme's proprietary Enhanze technology to Roche's biological therapeutic compounds. Under the terms of the agreement, Roche made an initial payment to Halozyme for the application of its recombinant human enzyme, rHuPH20, to three pre-defined biologic targets exclusive to Roche. In December 2008, Roche selected a fourth biologic target followed by selection of a fifth target in June 2009 and has the option to exclusively develop and commercialize rHuPH20 with an additional three potential targets. Pending the successful achievement of a series of clinical, regulatory, and sales events, Roche will pay Halozyme additional milestones as well as royalties on future product sales. Under the collaboration, Roche has access to Halozyme's expertise in developing and applying rHuPH20 to Roche biologics directed at multiple targets. Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and Roche compounds resulting from the collaboration.

    Dirk
  10. [verwijderd] 22 februari 2011 14:56
    Geen geweldige deal, helaas.

    Forest Labs To Buy Clinical Data For At Least $898.7 Million

    Last update: 2/22/2011 8:33:44 AM

    DOW JONES NEWSWIRES Forest Laboratories Inc. (FRX) said it will buy Clinical Data Inc. (CLDA) for at least $898.7 million, as it looks to capitalize on Clinical Data's newly approved Viibryd antidepressant drug. According to terms of the deal, Forest Labs will pay $30 a share in cash for each Clinical Data share--a 12% discount from their closing price of $33.90 on Friday. The deal also includes a contingent consideration of $6 a share based on milestones related to Viibryd that could boost the price tag on the deal to $1.08 billion.

    Shares of Forest Labs plunged 6.8% to $32 in premarket trading as the company said the deal is expected to hurt its per-share earnings for the next three fiscal years, with the bottom line being dinged by 55 cents to 65 cents a share for fiscal 2012. Forest Labs said the deal may add to its bottom line during fiscal 2014.

    Clinical Data shares closed Friday at $33.90 and were inactive premarket. Forest Labs noted that the $30-a-share offer is a 6.6% premium to the average trading price of Clinical Data stock since the first trading day after it announced the approval of Viibryd.

    "We believe that we are uniquely positioned to bring Viibryd to market in light of our long and successful experience of clinical development and expertise in the antidepressant market," said Forest Labs Chairman and Chief Executive Howard Solomon. "This transaction is consistent with our strategy to acquire new products that will help offset the loss of revenues due to patent expiries."

    Consolidation has been a theme of the drug-making and developing industry of late, as companies have been buying each other up in an attempt to insulate themselves from revenue lost when patents on drugs expire, allowing much cheaper generic versions of drugs to hit the market. The deal has been approved by both companies' boards of directors and is expected to close in the second quarter.
  13. [verwijderd] 1 maart 2011 13:55
    Halozyme Therapeutics to Present at Two Investor Conferences in March
    Last update: 3/1/2011 7:30:00 AM

    SAN DIEGO, March 1, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. (HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at two investor conferences during March. Cowen and Company 31st Annual Health Care Conference, Boston, Mass., Tuesday, March 8, 2011, 9:30 a.m. ET (6:30 a.m. PT) Barclays Capital 2011 Global Healthcare Conference, Miami, Fla., Wednesday, March 16, 2011, 4:45 p.m. EDT (1:45 p.m. PDT) To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at . The replays will be available for 90 days after each event.

    Dirk
  14. [verwijderd] 1 maart 2011 14:02
    The Next Big Move For The Smartest Biotech Investor
    Feb. 22 2011 - 10:04 am

    Randal J. Kirk, worth $2.2 billion, is one of the only billionaires to make his money from biotech. He may just be the best biotech investor ever. He made $1.2 billion when he sold his New River Pharmaceuticals and its ADHD drug Vyvanse to Shire in 2007. Now he just made another score by selling his antidepressant company Clinical Data to Forest Laboratories for $1.2 billion, or $30 a share in cash plus $6 per share more if sales milestones are met.

    Kirk’s strategy is to buy obscure companies at a very low price, stay the course until a drug gets to the market–without getting attached to any one plan, and sell at a good price to drug companies that need product.

    But what Kirk really wants to do is change the world. He says his new synthetic biology company Intrexon will be far bigger than anything he has done before. It is working on better protein-based drugs, gene therapy, industrial enzymes, and ag-biotech. Almost nobody has heard of it and its lead scientist Thomas Reed. Kirk calls Reed “the Henry Ford of DNA” and says the new company will someday be the Google of the life sciences.

    Forbes Magazine profiled Kirk and his new company in the upcoming March 14th issue. It is the last co-bylined Forbes article written by Matt Herper and myself; I will soon be taking another job at a competitor. Here is the story, which went to press a few days before Clinical Data was sold:

    Grand Plans

    Investor Randal J. Kirk became very rich making small improvements to old drug classes. Now he and partner Thomas Reed want to change the world.

    By Robert Langreth and Matthew Herper

    Biotechnology produces few billionaires. The high costs of drug development mean that most early investors no longer own big stakes by the time a medicine finally gets to market. Randal J. Kirk, a Virginia biotech investor whose net worth FORBES estimates at $2.2 billion, upends this rule. Instead of spreading his bets and taking profits early like most venture capitalists, Kirk bets big on a few small companies and stays the course until a product gets to market. He reaped $1.2 billion in 2007 when he sold his New River Pharmaceuticals and its attention deficit disorder drug to Shire for $2.6 billion. His next big score could come from his biotech company Clinical Data, whose antidepressant Viibryd was approved in January. Its shares have doubled this year on speculation that Kirk will soon sell to a big drug company desperate for new products. Kirk, with common stock, convertible notes and warrants, is sitting on a 52% stake worth over $600 million. [Note: Clinical Data today announced plans to sell to Forest.]

    But Kirk says everything he has done in the past pales next to the potential of his latest project: Intrexon, a secretive research-stage company that is working on the hot new field of synthetic biology—basically genetic engineering on steroids. Kirk and his investment fund, Third Security, have poured $200 million into the closely held 180-person company based in Blacksburg, Va., which has no drugs on the market.

    “I’ve been a biotech investor for 27 years, and Intrexon is by far the best thing I’ve ever seen,” says Kirk, 56, who raises falcons and composes electronic music on a 7,200-acre cattle farm in rural Pulaski County, Va. He likens Intrexon to “the Google of the life sciences” and predicts that in a decade it could become “the largest, most significant company” in its burgeoning field.

    Today’s biotech industry makes modest genetic tweaks to living cells—adding or deleting single genes so bacteria will produce insulin or corn will resist pests, for example. Synthetic biology aims to make much more radical changes and reengineer living cells from the ground up. One goal is to make protein drugs far more cheaply and efficiently than is ­possible today. Another is to transform living cells into tiny molecular factories to make everything from gasoline to ­construction materials. Some scientists even want to create entire new life forms from scratch.

  15. [verwijderd] 1 maart 2011 14:02
    Lots of big scientific names are working in synthetic biology, which so far has produced lots of hype and headlines but few practical breakthroughs. Gene jockey J. Craig Venter, known for sequencing the first human genome in 2000, leads a company called Synthetic Genomics that has a $300 million deal with ExxonMobil to make designer biofuels.

    Intrexon has released few details about which products it is pursuing. Its lead drug is only at the earliest stage of human trials. It is so obscure that three prominent synthetic biology researchers contacted by FORBES—including Venter—said they had never heard of it. Kirk shrugs. Among other colossal ambitions, he wants to revitalize the troubled field of gene therapy, make dozens of inexpensive protein drugs and produce better genetically engineered crops that will benefit consumers, not just farmers. The company is also working on biofuels, designer enzymes, bioplastics and unspecified consumer products. Keeping the work secret is part of the plan, Kirk says. “If we were in the business of publishing, we could get the cover of Science magazine any issue we wanted,” he boasts.

    The scientist behind Kirk’s mystery company is the 45-year-old molecular geneticist Thomas Reed. He founded Intrexon in 1998 while still completing his Ph.D. and postdoctoral work in cardiovascular genetics at the University of Cincinnati. “I think of him as the Henry Ford of DNA,” says Kirk. “We are all living in his dream.”

    Reed says he got the idea for the company after watching The Graduate, where Dustin Hoffman’s character is urged to go into plastics. At the time the genome was being sequenced, and researchers promised it would quickly lead to huge numbers of breakthrough drugs. Reed figured what bioengineers needed to turn fantasy to fact was a library of standardized DNA components that could then be used to construct designer genes from scratch. He has spent the last ten years trying to build them and has come up with of 70,000 DNA parts that can be used to control gene expression.

    The company struggled until Reed moved to Blacksburg in 2004 in order to get some economic development money. That led to a small investment from Kirk’s nearby Third Security venture firm and then a meeting and dinner with Kirk in 2006. After the presentation, Reed says, Kirk “walked up to me and said, ‘You have some really good stuff, and we are going to help you.’” The two hit it off and started having martinis together at BT’s Restaurant in Radford, Va. near Kirk’s offices and farm, hatching grand plans.

    Reed’s original idea was to be a service business that sold DNA parts to researchers in academia and industry. Kirk encouraged Reed to think much bigger. In 2009 Kirk took over as chief executive and created distinct divisions for making various applications of Reed’s modular DNA technology. One unit in Foster City, Calif. is working on manufacturing proteins using Reed’s DNA control technology, perhaps to create generic knockoffs of expensive biotech drugs like growth hormone and Epogen. An agricultural division is based in North Carolina, and an industrial products division is seeking a home in the Bay Area.

    One of Intrexon’s many goals is to revive the troubled field of gene therapy—the idea of curing deadly diseases by transplanting new genes into cells. For years gene therapy has stalled because of researchers’ inability to control where the genes are going inside cells. This has led to a lack of efficacy and to major safety problems when genes go to the wrong places.

    Intrexon’s gene therapy method, now in early human trials, aims to deliver powerful immune system proteins just where they are needed to kill cancer cells while avoiding healthy tissues. The first version of it, in testing for metastatic melanoma, takes immune system dendritic cells from the body and modifies them with Reed’s synthetic DNA so they can produce high levels of a cancer-killing protein called IL-12. They are injected back into the tumor, where they become little bioreactors that release IL-12. Sharpening its efficacy, the gene therapy is not activated until a patient takes a pill, controlling how much of the protein is released at what time.

    To move the gene therapy work forward, Kirk inked a deal in January for a 12% stake of Ziopharm Oncology, a biotech company led by former Memorial Sloan-Kettering Cancer Center surgeon Jonathan Lewis. It will move the IL-12 drug and other cancer gene therapy approaches through human trials while Intrexon continues to work on basic science.

    Will Kirk’s grand plans for Intrexon pan out? His other companies provide some clues. Kirk has big dreams but ultimately is a pragmatic businessman. He has a knack for buying a big stake for a low price, getting a drug to the market and selling at a big profit. Ordinary investors in his public companies get a chance to participate in the gains.

    “I think he’s the great pharmaceutical salesman of our age,” says Harry M. Tracy, who runs the newsletter NeuroInvestment Research. Tracy argues Kirk is better at making money than developing medically important drugs. “When it’s Randal Kirk, he might be able to take a bad hand and do something with it,” he says. “Big money, not so big clinically.”

    Example: the attention deficit disorder drug Vyvanse that first made Kirk a billionaire. It has a special ultra-long-acting mechanism that also aimed to make it more abuse resistant than standard stimulants. After it got to market in 2007, the Drug Enforcement Administration and FDA put it on the same abuse schedule as other stimulants. Kirk “convinced Shire they should spend $2.6 billion to buy a drug that is essentially the same as [Shire’s old ADHD drug] Adderall XR,” says Tracy. Kirk says Vyvanse is clearly better. You can’t argue with its sales, now $632 million and projected to top $1 billion.

    Kirk’s antidepressant company, Clinical Data, also once had grander plans. It was going to help create a new field, “pharmacogenomics,” in which genetic tests are used to help choose the best drugs for each patient. There was even a test that was going to go with the antidepressant to predict which patients would respond to it.

    The antidepressant gene test failed in trials, and Clinical Data sold the pharmacogenomics business. Kirk still believes that pharmacogenomics will work but says it is progressing at a much slower pace than drugs. He calls the antidepressant Viibryd “the first genuinely new antidepressant in 14 or 15 years,” and adds, “I haven’t spoken to anyone who doesn’t appreciate the differentiation this has.” He may want to reach out to Columbia University psychiatrist Jeffrey Lieberman. “To make statements that it has clearly better safety or efficacy based on this data is really stretching it,” says Lieberman. Debates over its merits won’t phase potential buyers—new twists on antidepressants have routinely been huge sellers.

    The Ziopharm-Intrexon deal gives Kirk an opportunity for a payday no matter what happens with the gene therapy. Ziopharm already has a drug for sarcoma in final-stage trials. Its shares would likely soar if this works. Kirk calls the sarcoma drug “a rounding error” in the types of multibillion-dollar sales he expects Intrexon will achieve. Changing the world is tough. Kirk has found a way of getting rich simply by trying.

    blogs.forbes.com/robertlangreth/2011/...

  16. [verwijderd] 7 maart 2011 12:24
    ZIOPHARM and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin in Asia

    Last update: 3/7/2011 6:05:00 AM

    NEW YORK & TOKYO, Mar 07, 2011 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (ZIOP), an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product (Zinapar(TM) or ZIO-101) and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

    Under the terms of the agreement,ZIOPHARM granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms, and related organic arsenic molecules, in all indications for human use in a pan-Asian/Pacific territory comprised of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand. ZIOPHARM will receive an up-front payment of $5 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory, and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones.

    ZIOPHARM will also be entitled to receive double digit royalty payments from Solasia on net sales of licensed products in the applicable territories, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for the development and commercialization of darinaparsin in the pan-Asian/Pacific territory, subject to input from a joint steering committee of the parties intended to align a strategy for worldwide development. The parties anticipate that ZIOPHARM will supply drug product for Solasia's clinical trials at Solasia's cost and ZIOPHARM expects to be responsible for the expenses of scale up commercial production worldwide.

    The parties may also carry out future joint development activities under a cost sharing arrangement. "This agreement marks an important milestone for our darinaparsin program, as it provides validation for the compound's clinical potential as well as additional support ahead of moving into the pivotal phase later this year," said Jonathan Lewis, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of ZIOPHARM. "Solasia is a strong partner whose management and advisory team are highly experienced in the development and commercialization of products within these territories."

    "We are very excited to add darinaparsin to our growing pipeline of oncology drugs. Cancer is a leading cause of death in Asia, with hematologic malignancies increasing as a subset of the total cancer incidence rate," said Steven E. Engen, President & CEO of Solasia. "Darinaparsin is well tolerated and is expected to be less toxic than arsenics commonly used in Japan, China and other territories in Asia and has demonstrated promising efficacy in hematologic cancers, including peripheral T-cell lymphoma (PTCL), a disease nearly twice as prevalent in Asia compared to the West, but for which there are very few treatment options. We look forward to working with ZIOPHARM in developing this novel drug, and to filling this growing unmet medical need in Asia."
  17. [verwijderd] 8 maart 2011 13:03
    ZIOPHARM to Present at Barclays Capital 2011 Global Healthcare Conference

    Last update: 3/8/2011 6:05:00 AM

    NEW YORK, Mar 08, 2011 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (ZIOP), announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the Barclays Capital 2011 Global Healthcare Conference on Tuesday, March 15, 2011 at 8:30 am Eastern Time, at the Loews Miami Hotel in Miami, Florida. Dr. Lewis will provide an overview of the Company and its clinical development programs.

    To access a live webcast of the presentation, please visit the Investor Relations section at . The webcast will be archived for ninety days.

  18. [verwijderd] 25 maart 2011 17:26
    Ziopharm Partners Up
    By Jonathan Moreland
    RealMoney Contributor
    3/23/2011 4:00 PM EDT

    Randall J. Kirk is a successful biotech CEO and investor known for taking large, concentrated bets in firms he believes in. I have him to thank for bringing Halozyme Therapeutics (HALO) to my attention way back in late 2006. I managed a 137% gain in that position over a 70-week period. Kirk recently had another big winner in Clinical Data (CLDA) .
    With a track record like his, it wasn't surprising that shares of Kirk's newest interest, Ziopharm Oncology (ZIOP) , popped as soon as his interest became known. On Jan. 6, Kirk's privately held biotech firm, Intrexon, announced a partnership agreement with Ziopharm. Ziopharm gained the rights to Intrexon's DNA-based UltraVector Technology to help it produce anti-cancer effectors in exchange for paying Intrexon 50% of net profits derived from the collaboration. Intrexon also received a tidy 3.6 million shares of ZIOP.
    In return, Intrexon agreed to invest up to $61.6 million in new Ziopharm shares. The first part of the Intrexon investment occurred on Jan. 12, when the firm purchased 2.4 million shares of ZIOP for $4.80 each. That reflected the price shares of ZIOP were trading at just before the deal was announced. But Kirk's Midas touch already built in a profit to the private placement by the time it was made. Undaunted by the price rise in ZIOP he had caused, Kirk's firm invested another $11 million in Ziopharm on Feb. 3, at $5.75 per share.
    After all that excitement, shares of Ziopharm have moved sideways in the past month, making ZIOP's price chart look like it is consolidating gains as logical technical support at its 50-day moving average rises to meet it.
    Even the best investors get it wrong now and then, of course, and Kirk's imprimatur should not be confused for a guarantee of further capital gains for ZIOP. The reality is the Ziopharm remains a development stage biotech with no expectation of earnings in the near future, which faces risks in terms reviews by the Food and Drug Administration (FDA) as it tries to commercialize products.
    Ziopharm is focused on developing a diverse portfolio of cancer therapeutics. The company currently has several clinical and preclinical programs under way involving drugs by the name of palifosfamide (ZIO-201), darinaparsin (ZIO-101), and indibulin (ZIO-301).
    Palifosfamide is a proprietary form of ifosfamide, which is presently used to treat testicular cancer, sarcoma and lymphoma. The problem is that ifosfamide has been shown to have some toxic side affects, a negative that is not as obvious in present trials of palifosfamide. Palifosfamide is currently in a phase II randomized controlled trial to treat soft-tissue sarcoma, with expectations of clinical results in mid 2012. Before then, enrollment in related phase III trials is expected by year's end. Both events could be stock-moving in nature.
    Darinaparsin is a mitochondrial-targeted agent in phase II trials for treating patients with lymphomas, and indibulin is an oral tubulin binding agent that has demonstrated significant anti-tumor activity in many types of cancer cells. Both compounds are expected to have early-stage trial results by late 2011.
    However, according to Ziopharm Vice President Michael King, "Synthetic biology is the biggest upside opportunity for Ziopharm." This is the DNA-based therapeutics aspect of Ziopharm's product roadmap that just got a boost from the collaboration with Intrexon.
    While some preliminary data may be available from the collaboration by year's end, meaningful clinical results from the Ziopharm/Intrexon partnership are likely years away. Still, King expects more specifics on the science behind the DNA-based approach to be released before 2011 is over in one or more scientific conferences.
    So for better or worse, make-or-break responses from the FDA are not expected for Ziopharm any time soon. That makes event risk less of a factor for ZIOP in the very near term, but it also means the company is that much further away from bringing in any potentially meaningful revenues. That makes this stock a high-risk/high-reward prospect as far as I'm concerned.
    Whatever one's assessment of Ziopharm's risk profile, however, Kirk has arguably increased the odds of success for the firm with his latest deal. Not only does Ziopharm get introduced to Intrexon's technology, it also gains access to its money -- as well as personal involvement from Kirk, who has assumed a board seat.
    Analysts at both Barclay's Capital and Jeffries certainly agree on the promise of the new Ziopharm. Both firms recently initiated research with Buy ratings on the stock, and price targets in the range of $8-$9.

  19. [verwijderd] 30 maart 2011 12:27
    2 arrested for insider trading on CLDA

    "WASHINGTON (AP) -- A chemist with the Food and Drug Administration and his son were arrested Tuesday on charges of running a $2.27 million insider trading scheme.

    Prosecutors say Cheng Yi Liang, 57, and his son, Andrew Liang, 25, used confidential information from a password-protected FDA tracking system to buy and trade the stocks of drug companies who had pending applications for products. Both were arrested Tuesday on charges including securities fraud and wire fraud and made an initial court appearance in U.S. District Court in Greenbelt, Md.

    A criminal complaint charges the men, both of Gaithersburg, Md., with trading on inside information from November 2007 to this month. Prosecutors say the father and son used the proceeds to pay for travel and credit card bills and to buy new cars, prosecutors said.

    Prosecutors say that by accessing an internal FDA database used to track and receive drug applications, Cheng Yi Liang repeatedly obtained inside information on when the agency would make a decision on drug applications and what that decision would be.

    He and his son would then use that information to purchase and trade the companies' shares days ahead of the FDA's formal announcement, according to the complaint. Federal authorities say software they installed on Cheng Yi Liang's work computer enabled them to take screen shots and keep tabs on his use of the database.

    The database contains a warning to users that is for "U.S.-government authorized use only."

    In one example cited by the complaint, the men allegedly acquired 48,875 shares of Clinical Data Inc. after learning through the secure database that the company's anti-depression drug, Viibryd, had been recommended for approval. The drug's approval was announced three days later, and the men sold their shares for a profit of more than $379,000, according to the complaint.

    The FDA said in a statement that it was aware of the arrests. Cheng Yi Liang has worked for the FDA since 1996.

    finance.yahoo.com/news/FDA-chemis...
38 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,25 -0,03%
EUR/USD 1,0870 +0,03%
FTSE 100 8.420,26 -0,22%
Germany40^ 18.716,50 -0,12%
Gold spot 2.415,21 0,00%
NY-Nasdaq Composite 16.685,97 -0,07%

Stijgers

NX FIL...
+8,76%
VIVORY...
+6,12%
Sif Ho...
+4,09%
RENEWI
+3,21%
HEIJMA...
+3,08%

Dalers

Corbion
-3,97%
ADYEN NV
-3,20%
EBUSCO...
-3,00%
SIGNIF...
-2,50%
PROSUS
-2,29%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!